cervical cancer occurred in regions with disproportionately high burdens of cervical cancer and underserved by national screening programmes.
Background: LITHE was a 2-year, randomized, double-blind study of tocilizumab (TCZ) in patients (pts) with moderate to severe RA who were inadequate responders to MTX, with an additional 3 years of open-label (OL) extension. Methods: 1190 pts were randomized (1:1:1) to TCZ (4 mg/kg [TCZ4] or 8 mg/kg [TCZ8]) or placebo every 4 weeks þ MTX (10-25 mg/week). Pts could receive rescue TCZ from week 16; after week 52, pts could switch to OL TCZ8. Radiographs were analysed by Genant-modified Total Sharp Score (GmTSS). Data were pooled for all pts who received !1 dose of TCZ (All TCZ). The proportions of pts who maintained efficacy responses consecutively for !24 weeks are summarized (Table 1) . Results: 1149 pts received !1 dose of TCZ with 4379.6 patient-years (PY) of exposure, and 34% received 5 years of treatment (All TCZ). Mean duration in the All TCZ population was 3.81 years with half the pts participating for !4.69 years. The mean change in GmTSS over 5 years showed a 56% greater inhibition of joint damage in pts randomized to TCZ vs placebo, with greatest annualized progression rate (APR) in year 1. 53% of TCZ pts had no progression (GmTSS 0) during the 5 years vs 35% of placebo pts (placebo pts may have switched to TCZ as early as week 16). Clinical benefit was maintained, as measured by ACR response, DAS28-ESR remission and EULAR good/moderate response. Overall rates/100PY of serious adverse events and serious infections were 11.67 and 3.42, respectively. Conclusion: During long-term treatment, TCZ þ MTX continued to inhibit radiographic progression. Improvements in signs and symptoms and in physical function were maintained with continued TCZ treatment. The safety profile at 5 years was similar to that previously observed. Disclosure statement: J.M.K. has received consultancy fees from Amgen, Abbott, BMS, Centocor, Genentech, Pfizer, Roche and UCB; and has received research support from Amgen, Abbott, BMS, Centocor, Genentech, Pfizer and Roche. A.H. has received honoraria from Roche. R.B.-V. has received consultancy fees from Abbott, Roche, Schering-Plough, Wyeth and Pfizer; and has been involved in a speakers' bureau for Abbott, Roche, Schering-Plough, Wyeth and Pfizer. C.M.M. is an employee of Roche. E.V. is an employee of Roche. R.F. has received research support from Roche. The other author has declared no conflicts of interest. 
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